Loading...
•
Mar 31, 2025
Akoya Q1 2025 Earnings Report
Akoya Biosciences reports first quarter 2025 financial results with a decrease in revenue and net loss, alongside an increase in gross margin.
Key Takeaways
Akoya Biosciences reported a revenue of $16.6 million for the first quarter of 2025, a decrease of 9.8% compared to the prior year. The company's net loss improved to -$15.652 million from -$23.484 million in the prior year period, and gross margin increased significantly to 59.3%.
Revenue for Q1 2025 was $16.6 million, down 9.8% year-over-year.
Gross margin improved to 59.3% in Q1 2025, up from 45.7% in the prior year period.
Net loss for Q1 2025 was -$15.652 million, an improvement from -$23.484 million in the prior year.
Operating expenses decreased by 22.3% to $23.3 million in Q1 2025.
Revenue by Segment
Forward Guidance
Akoya will not be hosting an earnings conference call or providing forward-looking guidance at this time due to the pending acquisition by Quanterix Corporation.
Positive Outlook
- Continued focus on operational discipline and innovation.
- Successful increase in installed base despite macroeconomic uncertainty.
- Technology gaining momentum globally, with growing adoption in large-scale population studies.
- Expanding publication footprint across key research areas in high-impact journals.
- Confidence in value-creating opportunities from the integration with Quanterix.
Challenges Ahead
- Broader macroeconomic uncertainty.
- NIH funding uncertainty.
- Pending acquisition by Quanterix Corporation means no earnings call.
- No forward-looking guidance provided at this time.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...